Doxazosin
Product Images NDC 43353-647

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 43353-647). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2mg (43353 647)

Label for Doxazosin Mesylate 2mg tablets, containing 90 tablets. The label shows the National Drug Code (NDC) 43353-0647-60 and indicates the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC, sourced from Mylan Pharmaceuticals Inc. It includes storage instructions and a caution to keep out of reach of children. The label states 'RX Only'.*

FDA Label Image

Bottle Label 4mg (43353 648)

Label for Doxazosin Mesylate 4 mg tablets, containing 90 tablets. The label indicates storage instructions and that the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC. It also includes manufacturer information for Mylan Pharmaceuticals Inc., Morgantown, WV, and is marked RX only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (A7293678 9b1b 4102 9a79 1000d853dc16 01)

Chemical structure of Doxazosin depicted as a molecular diagram showing the arrangement of atoms and bonds, including a methanesulfonic acid (CH3SO3H) component.*

FDA Label Image

Figure 1 (A7293678 9b1b 4102 9a79 1000d853dc16 02)

Figure 1 consists of two line graphs depicting study results for Doxazosin versus placebo. The left graph shows the mean change in total symptom score from baseline over 14 weeks, with Doxazosin showing a greater decrease than placebo. The right graph shows the mean increase in maximum urinary flow rate from baseline over the same duration, with Doxazosin demonstrating a higher increase compared to placebo.*

FDA Label Image

Table 1 (A7293678 9b1b 4102 9a79 1000d853dc16 03)

A clinical study data table and corresponding bar chart showing symptom scores and maximum flow rate changes for Doxazosin compared to placebo. The table summarizes mean baseline and mean change values from three studies involving different dosing regimens, highlighting statistically significant improvements in symptom scores and maximum flow rate with Doxazosin doses of 4 mg and 8 mg. The bar chart visually represents maximum flow rate improvements in Study 2, indicating incremental benefits with increasing Doxazosin doses over placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.